A new era of psoriasis treatment: Drug repurposing through the lens of nanotechnology and machine learning

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125385 - 125385

Published: Feb. 1, 2025

Language: Английский

---

The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5977 - 5977

Published: May 29, 2024

Human mycoses cover a diverse field of fungal diseases from skin disorders to systemic invasive infections and pose an increasing global health problem based on ineffective treatment options, the hampered development new efficient drugs, emergence resistant strains. Niclosamide is currently applied for worm infections. Its mechanisms action, which include suppression mitochondrial oxidative phosphorylation (also known as uncoupling), among others, has led repurposing this promising anthelmintic drug therapy further human such cancer, diabetes, microbial Given urgent need develop drugs against infections, considerable antifungal properties niclosamide are highlighted in review. chemical pharmacological relevant also briefly mentioned, described mitochondria-targeting action add current arsenal approved drugs. In addition, activities salicylanilide-based analogs pathogens, including agents veterinary medicine many years, discussed their feasibility antifungals humans. Preliminary structure-activity relationships determined discussed. Various salicylanilide derivatives with showed increased oral bioavailabilities when compared niclosamide. The simple synthesis vouchsafes broad cost-effective availability poorer patient groups. Pertinent literature covered until 2024.

Language: Английский

---

Revisiting Niclosamide Formulation Approaches – a Pathway Toward Drug Repositioning

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 4153 - 4182

Published: Sept. 1, 2024

Niclosamide (NIC), an anthelmintic drug, has garnered recent attention for its potential as antiviral, antibacterial, and chemotherapeutic agent, among other applications. Repurposing NIC presents a current trend, offering significant time cost savings compared to developing entirely new therapeutic chemical entities. However, drawback lies in poor solubility, resulting notably low oral bioavailability. This review consolidates efforts overcome this limitation by summarizing twelve categories of formulations, spanning derivatives, amorphous solid dispersions, co-crystals, nanocrystals, micelles, nanohybrids, lipid nanoparticles emulsions, cyclodextrins, polymeric nanoparticles, dry powders inhalation, 3D printlets, nanofibers. These formulations cover oral, injectable, inhalable potentially (trans)dermal routes administration. Additionally, we present comprehensive overview characteristics, including physico-chemical properties, metabolism, safety, pharmacokinetics. Moreover, identify gaps formulation administration pathways that warrant further investigation address

Language: Английский

---

Niclosamide: CRL4^AMBRA1 mediated degradation of cyclin D1 following mitochondrial membrane depolarization

RSC Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Niclosamide, an FDA-approved anthelmintic drug, known to uncouple the mitochondria induces cyclin D1 degradation via CRL4 AMBRA1 . We find a striking correlation between two processes and that it is observed amongst various compounds.

Language: Английский

---

Findings from the individualized management of a patient with acyl-CoA Oxidase-1 (ACOX1) deficiency: A bedside-to-bench-to-bedside strategy

Molecular Genetics and Metabolism, Journal Year: 2024, Volume and Issue: 143(3), P. 108581 - 108581

Published: Sept. 28, 2024

Language: Английский

---